{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T21:53:27Z","timestamp":1774648407535,"version":"3.50.1"},"reference-count":25,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2018,3,30]],"date-time":"2018-03-30T00:00:00Z","timestamp":1522368000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100011284","name":"Valeant Pharmaceuticals International","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011284","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2018,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Patients with psoriasis have lesional symptoms, including itch, which can reduce quality of life. The efficacy and safety of brodalumab, an interleukin\u201017 receptor A antagonist, in treating moderate\u2010to\u2010severe psoriasis have been reported in three randomized, controlled, phase 3 trials (<jats:styled-content style=\"fixed-case\">AMAGINE<\/jats:styled-content>\u20101\/\u20102\/\u20103).<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>The effect of brodalumab on lesional symptoms was assessed using the psoriasis symptom inventory (<jats:styled-content style=\"fixed-case\">PSI<\/jats:styled-content>), a validated patient\u2010reported instrument.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients were randomized to receive brodalumab (140 or 210\u00a0mg every 2\u00a0weeks [Q2W]), placebo (<jats:styled-content style=\"fixed-case\">AMAGINE<\/jats:styled-content>\u20101\/\u20102\/\u20103), or ustekinumab (<jats:styled-content style=\"fixed-case\">AMAGINE<\/jats:styled-content>\u20102\/\u20103) during a 12\u2010week induction phase, followed by a maintenance phase through week 52. Patients electronically rated the severity of <jats:styled-content style=\"fixed-case\">PSI<\/jats:styled-content> items (itch, burning, stinging, pain, redness, scaling, cracking and flaking) during the previous 24\u00a0h on a scale of 0 (not at all severe) to 4 (very severe). At each visit, the <jats:styled-content style=\"fixed-case\">PSI<\/jats:styled-content> total score responder status was assessed, with responders defined as having an average weekly total inventory score \u22648 with no item score &gt;1 at week 12.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Across <jats:styled-content style=\"fixed-case\">AMAGINE<\/jats:styled-content>\u20101\/\u20102\/\u20103, brodalumab was associated with improvements in <jats:styled-content style=\"fixed-case\">PSI<\/jats:styled-content> total scores and itch scores vs. placebo from week 2 through week 12 (<jats:italic>P\u00a0<\/jats:italic>&lt;\u00a00.001 in both domains). In <jats:styled-content style=\"fixed-case\">AMAGINE<\/jats:styled-content>\u20102\/\u20103, brodalumab 210\u00a0mg Q2W demonstrated faster onset of <jats:styled-content style=\"fixed-case\">PSI<\/jats:styled-content> total score and itch responses (week 2, 22.1% and 36.4%, respectively) vs. ustekinumab (week 2, 6.9% and 17.1%, respectively) and was associated with improved itch responses vs. ustekinumab after 52\u00a0weeks of constant treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Brodalumab demonstrated rapid, robust improvements in symptoms assessed by the <jats:styled-content style=\"fixed-case\">PSI<\/jats:styled-content>, including itch, vs. placebo and ustekinumab.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jdv.14913","type":"journal-article","created":{"date-parts":[[2018,3,7]],"date-time":"2018-03-07T06:33:33Z","timestamp":1520404413000},"page":"1305-1313","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Improvement in itch and other psoriasis symptoms with brodalumab in phase 3 randomized controlled trials"],"prefix":"10.1111","volume":"32","author":[{"given":"A.B.","family":"Gottlieb","sequence":"first","affiliation":[{"name":"New York Medical College, at Metropolitan Hospital New York NY USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Gordon","sequence":"additional","affiliation":[{"name":"Medical College of Wisconsin Milwaukee WI USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Hsu","sequence":"additional","affiliation":[{"name":"Temple University School of Medicine Philadelphia PA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Elewski","sequence":"additional","affiliation":[{"name":"University of Alabama at Birmingham School of Medicine Birmingham AL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.F.","family":"Eichenfield","sequence":"additional","affiliation":[{"name":"University of California San Diego School of Medicine and Rady Children's Hospital San Diego CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Kircik","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai New York NY USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Rastogi","sequence":"additional","affiliation":[{"name":"Ortho Dermatologics Bridgewater NJ USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Pillai","sequence":"additional","affiliation":[{"name":"Dow Pharmaceutical Sciences (a division of Valeant Pharmaceuticals North America LLC) Petaluma CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Israel","sequence":"additional","affiliation":[{"name":"Valeant Pharmaceuticals North America LLC Bridgewater NJ USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,3,30]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13065"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-015-0169-x"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1201\/b16573-5"},{"key":"e_1_2_6_5_1","first-page":"227","article-title":"Treating itch in psoriasis","volume":"18","author":"Dawn A","year":"2006","journal-title":"Dermatol Nurs"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-016-0213-5"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-2433"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S4465"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.09.030"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-2177"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1155\/2007\/64727"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbi.2014.03.004"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-042915-103905"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2008.08902.x"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.07.034"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.13236"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503824"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14493"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.3109\/09546634.2012.742950"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.3109\/09546634.2012.759639"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.3109\/09546634.2013.769042"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-7-62"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.03.026"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12761"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14464"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60125-8"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjdv.14913","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.14913","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,17]],"date-time":"2023-09-17T22:14:26Z","timestamp":1694988866000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.14913"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,30]]},"references-count":25,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["10.1111\/jdv.14913"],"URL":"https:\/\/doi.org\/10.1111\/jdv.14913","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,30]]},"assertion":[{"value":"2017-10-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-01-22","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-03-30","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}